Mok, T.S.K.;
Shaw, A.T.;
Camidge, R.D.;
Gadgeel, S.M.;
Rosell, R.;
Dziadziuszko, R.;
Kim, D.-W.;
Perol, M.;
Ou, S.-H.;
Bordogna, W.;
Smoljanović, V.;
Hilton, M.;
Peters, S.
Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC
Contributor:
Mok, T.S.K.;
Shaw, A.T.;
Camidge, R.D.;
Gadgeel, S.M.;
Rosell, R.;
Dziadziuszko, R.;
Kim, D.-W.;
Perol, M.;
Ou, S.-H.;
Bordogna, W.;
Smoljanović, V.;
Hilton, M.;
Peters, S.
Published:
Elsevier BV, 2019
Published in:
Annals of Oncology, 30 (2019), Seite v607